Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Nandakumar Packiriswamy"'
Autor:
Miguel Á. Muñoz-Alía, Rebecca A. Nace, Baskar Balakrishnan, Lianwen Zhang, Nandakumar Packiriswamy, Gagandeep Singh, Prajakta Warang, Ignacio Mena, Riya Narjari, Rianna Vandergaast, Kah-Whye Peng, Adolfo García-Sastre, Michael Schotsaert, Stephen J. Russell
Publikováno v:
mBio, Vol 15, Iss 2 (2024)
ABSTRACT Serum titers of SARS-CoV-2-neutralizing antibodies (nAbs) correlate well with protection from symptomatic COVID-19 but decay rapidly in the months following vaccination or infection. In contrast, measles-protective nAb titers are lifelong af
Externí odkaz:
https://doaj.org/article/cd8acd208724481bb4522d65973e788c
Autor:
Katherine E. R. Smith, Kah-Whye Peng, Jose S. Pulido, Adam J. Weisbrod, Carrie A. Strand, Jacob B. Allred, Alysha N. Newsom, Lianwen Zhang, Nandakumar Packiriswamy, Timothy Kottke, Jason M. Tonne, Madelyn Moore, Heather N. Montane, Lisa A. Kottschade, Robert R. McWilliams, Arkadiusz Z. Dudek, Yiyi Yan, Anastasios Dimou, Svetomir N. Markovic, Mark J. Federspiel, Richard G. Vile, Roxana S. Dronca, Matthew S. Block
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
IntroductionMetastatic uveal melanoma (MUM) has a poor prognosis and treatment options are limited. These patients do not typically experience durable responses to immune checkpoint inhibitors (ICIs). Oncolytic viruses (OV) represent a novel approach
Externí odkaz:
https://doaj.org/article/0a92140d4f6e43bc9b4331d5a320712f
Autor:
Paul Young, Erol Wiegert, Tanner Miest, Bradley Leibovich, Stephen Bardot, Stephen Boorjian, Mark Gonzalgo, Loren Herrera-Hernandez, Matthew Tollefson, Jeffrey Karnes, Paige Nichols, Tessa Kroeninger, Rachel Graham, Carole Lahana, Monica Reckner, Alysha Newsom, Nandakumar Packiriswamy, Janice Anoka, Kah Whye Peng, Alice Bexon, Shruthi Naik
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
Externí odkaz:
https://doaj.org/article/24995871bb594209b9f369d207fd230f
Autor:
Nandakumar Packiriswamy, Jeff Gandy, Sara N. Smith, Harry L. T. Mobley, Lorraine M. Sordillo, Sargurunathan Subashchandrabose
Publikováno v:
Mediators of Inflammation, Vol 2017 (2017)
Urinary tract infection (UTI) is an extremely common infectious disease. Uropathogenic Escherichia coli (UPEC) is the predominant etiological agent of UTI. Asymptomatic bacteriuric E. coli (ABEC) strains successfully colonize the urinary tract result
Externí odkaz:
https://doaj.org/article/fc8bf4d07a0d42e6a8a8acb672746dc6
Publikováno v:
Mediators of Inflammation, Vol 2016 (2016)
Inflammation is an essential host response during bacterial infections such as bovine mastitis. Endothelial cells are critical for an appropriate inflammatory response and loss of vascular barrier integrity is implicated in the pathogenesis of Strept
Externí odkaz:
https://doaj.org/article/feef01d724924438b3eeb8b8410eb161
Autor:
Haifei Jiang, Rebecca Nace, Emily Ariail, Yejun Ma, Erin McGlinch, Coryn Ferguson, Talia Fernandez Carrasco, Nandakumar Packiriswamy, Lianwen Zhang, Kah Whye Peng, Stephen J. Russell
Oncolytic virotherapy aims to activate host antitumor immunity, but the effectiveness of current intratumoral herpes-simplex virus (HSV) based monotherapy is limited. Here, to boost the potency of cancer cell targeting α-herpesviruses derived from H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e690ed8a6aba71931ada88c8c185cd7d
https://doi.org/10.21203/rs.3.rs-2817662/v1
https://doi.org/10.21203/rs.3.rs-2817662/v1
Autor:
Miguel Á. Muñoz-Alía, Rebecca A. Nace, Baskar Balakrishnan, Lianwen Zhang, Nandakumar Packiriswamy, Gagandeep Singh, Prajakta Warang, Ignacio Mena, Riya Narjari, Rianna Vandergaast, Adolfo García-Sastre, Michael Schotsaert, Stephen J. Russell
Publikováno v:
bioRxiv
Serum titers of SARS-CoV-2 neutralizing antibodies (nAb) correlate well with protection from symptomatic COVID-19, but decay rapidly in the months following vaccination or infection. In contrast, measles-protective nAb titers are life-long after meas
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51e9d892f0a6253ee8d6f4abb86a64f3
https://europepmc.org/articles/PMC9774211/
https://europepmc.org/articles/PMC9774211/
Autor:
Katherine E. Smith, Adam Weisbrod, Carrie Strand, Jacob Allerd, Jose S. Pulido, Alysha Newsom, Lianwen Zhang, Nandakumar Packiriswamy, Heather Montane, Lisa Kottschade, Anastasios Dimou, Yiyi Yan, Markovic Svetomir, Kah Whye Peng, Richard G. Vile, Matthew S. Block, Roxana S. Dronca
Publikováno v:
Cancer Research. 83:CT207-CT207
Oncologic viruses (OV) can induce tumor death through both direct oncolysis and immune-mediated destruction. Our study investigates the use of a novel OV with a Vesicular Stomatitis Virus (VSV) vector modified to express interferon-beta (IFN-b) and T
Autor:
Joselle Cook, Kah Whye Whye Peng, Thomas E. Witzig, Stephen M Broski, Jose Caetano Villasboas, Jonas Paludo, Mrinal M Patnaik, vincent Vincent rajkumar, Angela Dispenzieri, Nelson Leung, Francis Buadi, Nora Nora Bennani, Stephen M. Ansell, Lianwen Zhang, Nandakumar Packiriswamy, Baskar Balakrishnan, Bethany Brunton, Marissa Giers, Brenda Ginos, Amylou C. Dueck, Susan Geyer, Morie A Gertz, Rahma Warsame, Ronald S. Go, Suzanne R Hayman, David Dingli, Shaji K Kumar, P. Leif Bergsagel, Javier Munoz, Wilson I Gonsalves, Taxiarchis V. Kourelis, Eli Muchtar, Prashant Kapoor, Robert A Kyle, Yi Lin, Mustaqeem Siddiqui, Amie Fonder, Miriam Hobbs, Yi Lisa Hwa, Shruthi Naik, Stephen J Russell, Martha Q Lacy
Publikováno v:
Blood Advances.
Clinical success with intravenous (IV) oncolytic virotherapy (OV) has to date been anecdotal. Here, we conducted a phase 1 clinical trial of systemic OV therapy and investigated the mechanisms of action in responding T-cell lymphoma (TCL) patients. A
Autor:
Cliona M. Rooney, Rosa Maria Diaz, Rehan Khan, Stephen J. Russell, Amber Miller, Yumei Zhou, Angela Dispenzieri, Deepak Upreti, Nandakumar Packiriswamy, Kah Whye Peng
Publikováno v:
Leukemia
Oncolytic virus therapy leads to immunogenic death of virus-infected tumor cells and this has been shown in preclinical models to enhance the cytotoxic T-lymphocyte response against tumor-associated antigens (TAAs), leading to killing of uninfected t